ClinicalTrials.gg
TerminatedNCT02588950Updated Oct 23, 2023Results posted

A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes

A Phase 1 interventional study of U-500R in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Terminated at 1 site in United States. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Why this study was terminated
Slow enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing insulin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 1 of them phase 3. Insulin · Diabetes Mellitus, Type 2.

Enrollment
48th of 54
11 · median 60
Started
2016
with 5 others
Phase 1
5 of 54
none open now
Registered
37th of 54
by date

Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, this one is the 48th largest by enrollment, is one of 6 that started in 2016, is one of 5 in phase 1, and was the 37th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing insulin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing insulin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this two-part study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. In Part A, each participant will receive two treatments, a single dose and a single dose with continuous infusion of U-500R insulin, both administered just under the skin. Participants who complete Part A will continue into Part B where they will be assigned to 1 of 2 treatments with U-500R insulin, injected either twice or three times daily under the skin for 5-10 days. This study can last from 7-14 weeks including initial screening and follow up.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females with type 2 diabetes mellitus (T2DM)
  • Are current users of U-100, U-200 and/or U-300 insulin/analog as, basal, premixed and/or basal/bolus delivered with any injection device (pens and/or syringe/vial but excluding continuous subcutaneous infusion (CSII)/insulin pump use in the preceding 3 months), taking a total daily dose (TDD) of greater than or equal to (≥) 150 units (U) or at least one dose greater than (>) 100 U as part of a multiple daily injection (MDI) regimen and TDD less than or equal to (≤)3.0 units per kilogram (U/kg)
  • Concomitant antihyperglycemic agent(s) (AHA) therapy may include: metformin (MET), dipeptidyl peptidase 4 inhibitors, pioglitazone (doses ≤30 milligrams per day (mg/day)), glucagon like peptide (GLP)-1 receptor agonists, sodium-glucose co-transporter-2 (SGLT2) inhibitors, except in combination with GLP-1 receptor agonists
  • Participant's antihyperglycemic agent (AHA) therapy must have been stable for ≥3 months (except for weekly GLP-1 receptor agonists which must have been stable for ≥4 months)
  • Have (HbA1c) 7.5-11.5 percent (%)

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus (T1DM), or other types of diabetes mellitus apart from T2DM
  • Have known or allergies to insulin, contained in insulin products, or related compounds
  • Have used U-500R within 3 months prior to screening
  • Have used rosiglitazone, pramlintide, once weekly or twice daily exenatide, or other injectable or oral antihyperglycemic agent(s) not listed in the inclusion criterion; or are taking oral antidiabetic medications at doses exceeding the respective product labels
  • Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia which may affect reliability of measurements
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Part A: U-500R Single Injection

    Bolus of U-500R administered via single subcutaneous (SC) injection.

    Drug: U-500R

  • Experimental
    Part A: U-500R CSII

    Bolus of U-500R administered via continuous subcutaneous insulin infusion (CSII).

    Drug: U-500R

  • Experimental
    Part B: U-500R TID

    U-500R administered thrice-daily (TID) via SC injection under steady state conditions for 5 to 10 days

    Drug: U-500R

  • Experimental
    Part B: U-500R BID

    U-500R administered twice-daily (BID) via SC injection under steady state conditions for 5 to 10 days

    Drug: U-500R

Interventions

  • DrugU-500R

    Also known as: Humulin R U-500, LY041001, Humulin

06

What researchers measure

Primary outcomes

  1. Part A: Pharmacokinetics (PK): Time to Maximum Drug Concentration (Tmax) of U-500R

    Part A: Pharmacokinetics (PK): Time to Maximum Drug Concentration (Tmax) of U-500R.

    Time frame: Period 1 and 2: -0.5, 0, 0.5, 1, 2, 3, 4, 6, 7, 8, 12, 16, 24 hours (h) post dose

  2. Part B: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to 24 Hours Postdose (AUC[0-24]) of U-500R

    Part B: Pharmacokinetics: Area Under the Concentration Versus Time Curve from Zero to 24 Hours Postdose (AUC\[0-24\]) of U-500R.

    Time frame: Period 3: -0.5, 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose

  3. Part B: Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of U-500R

    Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of U-500R.

    Time frame: Period 3: -0.5, 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose

  4. Part B: Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax) of U-500R

    Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax) of U-500R.

    Time frame: Period 3 day 1: 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18h post dose

Secondary outcomes

  1. Part A: Pharmacokinetics: Area Under The Concentration Versus Time Curve From Time Zero to Last Time Point With A Measurable Concentration (AUC[0-tlast]) of U-500R

    Part A: Pharmacokinetics: Area Under The Concentration Versus Time Curve From Time Zero to Last Time Point With A Measurable Concentration (AUC\[0-tlast\]) of U-500R.

    Time frame: Period 1 and 2: -0.5, 0, 0.5, 1, 2, 3, 4, 6, 7, 8, 12, 16, 24h post dose

  2. Part A: Pharmacodynamics (PD): Time to Rmax (tRmax) of U-500R

    Part A: Pharmacodynamics (PD): Time to Rmax (tRmax) of U-500R.

    Time frame: Period 1 and 2: 0, 0.5, 1, 2, 3, 4, 6, 7, 8, 12, 16, 24h post dose

  3. Part B: Pharmacokinetics: Time to Maximum Concentration (Tmax) of U-500R

    Part B: Pharmacokinetics: Time to Maximum Concentration (Tmax) of U-500R.

    Time frame: Period 3: -0.5, 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose

  4. Part B: Pharmacodynamics: Total Amount of Glucose Infused (Gtot) of U-500R

    Pharmacodynamics: Total Amount of Glucose Infused (Gtot) of U-500R.

    Time frame: Period 3: 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose

  5. Part B: Pharmacodynamics: Time to Rmax (tRmax) of U-500R

    Part B: Pharmacodynamics: Time to Rmax (tRmax) of U-500R.

    Time frame: Period 3: 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose

07

Results

Posted Oct 18, 2023

Participant flow

Two parts study with Part A (Periods 1 \& 2) \& Part B (Period 3). Part A:Participants received study drug either by subcutaneous(SC) or continuous subcutaneous insulin infusion (CSII) as per the dosing sequence. Part B: Participants received study drug via SC injection either twice daily (BID) or three times daily (TID) as per the dosing sequence.

Period 1 (Part A)
Participant flow — Period 1 (Part A)
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started3233
Received at least one dose of study drug3233
Completed3233
Not completed0000
Period 2 (Part A)
Participant flow — Period 2 (Part A)
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started3233
Completed3223
Not completed0010
Withdrew: Withdrawal by subject0010
Period 3 (Part B)
Participant flow — Period 3 (Part B)
MilestoneSequence 1Sequence 2Sequence 3Sequence 4
Started3223
Completed3222
Not completed0001
Withdrew: Withdrawal by subject0001

Outcome measures

PrimaryPart A: Pharmacokinetics (PK): Time to Maximum Drug Concentration (Tmax) of U-500R

Part A: Pharmacokinetics (PK): Time to Maximum Drug Concentration (Tmax) of U-500R.

Time frame:
Period 1 and 2: -0.5, 0, 0.5, 1, 2, 3, 4, 6, 7, 8, 12, 16, 24 hours (h) post dose
Reported as:
Median · Hours (h)
Part A: Pharmacokinetics (PK): Time to Maximum Drug Concentration (Tmax) of U-500R
Hours (h)100-U Bolus U-500R SC100-U Bolus U-500R CSII
Part A: Pharmacokinetics (PK): Time to Maximum Drug Concentration (Tmax) of U-500R6 (0.5 to 8)5 (0.5 to 12)
Statistical analysis
  • 100-U Bolus U-500R SC vs 100-U Bolus U-500R CSII · Mixed Models Analysis · Geometric lsmean ratio: 1.46 · 90% CI 1.08 to 1.97
PrimaryPart B: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to 24 Hours Postdose (AUC[0-24]) of U-500R

Part B: Pharmacokinetics: Area Under the Concentration Versus Time Curve from Zero to 24 Hours Postdose (AUC\[0-24\]) of U-500R.

Time frame:
Period 3: -0.5, 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose
Reported as:
Geometric mean · Picomoles hour per liter (pmol*h/L)
Part B: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to 24 Hours Postdose (AUC[0-24]) of U-500R
Picomoles hour per liter (pmol*h/L)U-500R BIDU-500R TID
Part B: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to 24 Hours Postdose (AUC[0-24]) of U-500R7790 ± 5711700 ± 77
PrimaryPart B: Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of U-500R

Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of U-500R.

Time frame:
Period 3: -0.5, 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose
Reported as:
Geometric mean · Pico mole per liter (Pmol/L)
Part B: Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of U-500R
Pico mole per liter (Pmol/L)U-500R BIDU-500R TID
Part B: Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of U-500R699 ± 471050 ± 82
PrimaryPart B: Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax) of U-500R

Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax) of U-500R.

Time frame:
Period 3 day 1: 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18h post dose
Reported as:
Geometric mean · Milligram per Minute (mg/min)
Part B: Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax) of U-500R
Milligram per Minute (mg/min)U-500R BIDU-500R TID
Part B: Pharmacodynamics: Maximum Glucose Infusion Rate (Rmax) of U-500R524 ± 30588 ± 28
SecondaryPart A: Pharmacokinetics: Area Under The Concentration Versus Time Curve From Time Zero to Last Time Point With A Measurable Concentration (AUC[0-tlast]) of U-500R

Part A: Pharmacokinetics: Area Under The Concentration Versus Time Curve From Time Zero to Last Time Point With A Measurable Concentration (AUC\[0-tlast\]) of U-500R.

Time frame:
Period 1 and 2: -0.5, 0, 0.5, 1, 2, 3, 4, 6, 7, 8, 12, 16, 24h post dose
Reported as:
Geometric mean · Picomole hours per liter (pmol^h/L)
Part A: Pharmacokinetics: Area Under The Concentration Versus Time Curve From Time Zero to Last Time Point With A Measurable Concentration (AUC[0-tlast]) of U-500R
Picomole hours per liter (pmol^h/L)100-U Bolus U-500R SC100-U Bolus U-500R CSII
Part A: Pharmacokinetics: Area Under The Concentration Versus Time Curve From Time Zero to Last Time Point With A Measurable Concentration (AUC[0-tlast]) of U-500R5230 ± 356070 ± 70
Statistical analysis
  • 100-U Bolus U-500R SC vs 100-U Bolus U-500R CSII · Mixed Models Analysis · Geometric lsmean ratio: 0.885 · 90% CI 0.761 to 1.03
SecondaryPart A: Pharmacodynamics (PD): Time to Rmax (tRmax) of U-500R

Part A: Pharmacodynamics (PD): Time to Rmax (tRmax) of U-500R.

Time frame:
Period 1 and 2: 0, 0.5, 1, 2, 3, 4, 6, 7, 8, 12, 16, 24h post dose
Reported as:
Geometric least squares mean · Hour (h)
Part A: Pharmacodynamics (PD): Time to Rmax (tRmax) of U-500R
Hour (h)100-U Bolus U-500R SC100-U Bolus U-500R CSII
Part A: Pharmacodynamics (PD): Time to Rmax (tRmax) of U-500R8.50 ± 318.53 ± 35
Statistical analysis
  • 100-U Bolus U-500R SC vs 100-U Bolus U-500R CSII · Median difference (final values): 0.900 · 90% CI -1.60 to 2.60
SecondaryPart B: Pharmacokinetics: Time to Maximum Concentration (Tmax) of U-500R

Part B: Pharmacokinetics: Time to Maximum Concentration (Tmax) of U-500R.

Time frame:
Period 3: -0.5, 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose
Reported as:
Median · Hours
Part B: Pharmacokinetics: Time to Maximum Concentration (Tmax) of U-500R
HoursU-500R BIDU-500R TID
Part B: Pharmacokinetics: Time to Maximum Concentration (Tmax) of U-500R15 (5 to 18)15 (7 to 15)
SecondaryPart B: Pharmacodynamics: Total Amount of Glucose Infused (Gtot) of U-500R

Pharmacodynamics: Total Amount of Glucose Infused (Gtot) of U-500R.

Time frame:
Period 3: 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose
Reported as:
Geometric mean · Grams (g)
Part B: Pharmacodynamics: Total Amount of Glucose Infused (Gtot) of U-500R
Grams (g)U-500R BIDU-500R TID
Part B: Pharmacodynamics: Total Amount of Glucose Infused (Gtot) of U-500R441 ± 27510 ± 28
SecondaryPart B: Pharmacodynamics: Time to Rmax (tRmax) of U-500R

Part B: Pharmacodynamics: Time to Rmax (tRmax) of U-500R.

Time frame:
Period 3: 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 11, 12, 13, 15, 18, 24h post dose
Reported as:
Geometric mean · Hours
Part B: Pharmacodynamics: Time to Rmax (tRmax) of U-500R
HoursU-500R BIDU-500R TID
Part B: Pharmacodynamics: Time to Rmax (tRmax) of U-500R12.4 ± 6413.8 ± 7

Adverse events

Collected over Up to 72 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
100-U Bolus U-500R SC0/11 (0%)0/11 (0%)4/11 (36.4%)
100-U Bolus U-500R CSII0/11 (0%)0/11 (0%)3/11 (27.3%)
U-500R BID0/4 (0%)0/4 (0%)2/4 (50%)
U-500R TID0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Showing 10 of 16
Most frequent other events
Event100-U Bolus U-500R SC100-U Bolus U-500R CSIIU-500R BIDU-500R TID
Oedema peripheralGeneral disorders0/110/111/40/6
Pain in extremityMusculoskeletal and connective tissue disorders0/110/111/40/6
CoughRespiratory, thoracic and mediastinal disorders0/110/111/40/6
Infusion site extravasationGeneral disorders0/110/110/41/6
Upper respiratory tract infectionInfections and infestations0/110/110/41/6
DiarrhoeaGastrointestinal disorders1/110/110/40/6
Gastrointestinal disorderGastrointestinal disorders0/111/110/40/6
Medical device site swellingGeneral disorders0/111/110/40/6
Peripheral swellingGeneral disorders1/110/110/40/6
Procedural complicationInjury, poisoning and procedural complications1/110/110/40/6

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Overall
Mean56.2 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female3
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall
Hispanic or Latino4
Not Hispanic or Latino7
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White6
More than one race1
Unknown or Not Reported0
Body mass index
Body mass index(Kilogram per square meter (kg/m^2))Overall
Mean39.63 ± 8.59
08

Study locations

1 site
  • Profil Institute for Clinical Research
    Chula Vista, California 91911, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in May 2017, 16 months.

Results were first posted in Oct 2023, 6 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2015
First posted
Oct 28, 2015
StartActual
Jan 12, 2016
Primary completionActual
May 25, 2017
CompletionActual
May 25, 2017
Results first posted
Oct 18, 2023
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02588950
Responsible party
Sponsor
First posted
Oct 28, 2015
Start date
Jan 12, 2016
Primary completion
May 25, 2017
Completion
May 25, 2017
Results posted
Oct 18, 2023
Last update
Oct 23, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion